The selection of leaders for key healthcare agencies will profoundly influence federal policy. One notable name is Dr. Mehmet Oz, who has been floated as a potential administrator of the Centers for Medicare and Medicaid Services (CMS). If appointed, Dr. Oz’s leadership could emphasize alternative medicine and cost containment strategies. However, Healthcare Dive points out concerns among some healthcare professionals about his unconventional medical views and their alignment with evidence-based practices.

Expansion of value-based care and potential adjustments to Medicare Advantage plans are widely speculated. However, AP News highlights conflicting views on whether Medicaid block grants will gain traction, as some states may push back on federal restructuring.

While a full repeal of the ACA seems unlikely due to entrenched support, changes to subsidies, marketplace regulations, and Medicaid expansion waivers could occur. According to NPR, Republicans may focus on scaling back ACA provisions to reduce federal spending.

Drug price negotiations and importation policies are expected to re-enter the spotlight. The Advisory Board notes that Trump has previously signaled interest in policies that challenge pharmaceutical pricing models, though implementation may hinge on Congressional dynamics.

Building on the previous administration’s embrace of telehealth, the new administration may invest in digital health and interoperability initiatives. However, regulatory rollbacks could create tension with privacy advocates.